Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26663206 | 0.92 | KMT2A (0.48) | KMT2ALMNASYKMT-CO2ATR | |
| SCHEMBL3484770 | 0.86 | KMT2A (0.50) | KMT2ALMNASYKMT-CO2ATR | |
| SCHEMBL14752250 | 0.84 | KMT2A (0.49) | KMT2ALMNASYKMT-CO2ATR | |
| SCHEMBL12759220 | 0.82 | SYK (0.36) | KMT2ALMNASYKPDPK1PAX8 | |
| SCHEMBL30548350 | 0.82 | LMNA (0.47) | KMT2ALMNASYKMT-CO2ATR | |
| SCHEMBL26188589 | 0.82 | LMNA (0.47) | KMT2ALMNASYKMT-CO2ATR | |
| SCHEMBL4407354 | 0.81 | SYK (0.34) | KMT2ALMNASYKPDPK1PAX8 | |
| SCHEMBL30672340 | 0.77 | SYK (0.32) | KMT2ALMNASYK | |
| SCHEMBL30871128 | 0.77 | SYK (0.32) | KMT2ALMNASYK | |
| SCHEMBL26839516 | 0.77 | SYK (0.32) | KMT2ALMNASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4525987-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-114450283-B | 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023022430-A1 | NOVEL MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AUTOIMMUNE DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023022430-A1 | NOVEL MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AUTOIMMUNE DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-02-23 | — | — | WO | disclosed |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2022-09-15 | — | — | US | disclosed |
| EP-4003988-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | disclosed |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | Bristol-Myers Squibb Company and Albany Molecular Research, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | Bristol-Myers Squibb Company and Albany Molecular Research, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | Bristol-Myers Squibb Company and Albany Molecular Research, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company and Albany Molecular Research, Inc | 2011-03-31 | — | — | US | disclosed |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company and Albany Molecular Research, Inc | 2011-03-31 | — | — | US | disclosed |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company and Albany Molecular Research, Inc | 2011-03-31 | — | — | US | disclosed |
| EP-2280956-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009149258-A2 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149259-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | KMT2A 931/4885LMNA 2931/4885SYK 3120/4885 |
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | IL17A, IL15, IL18 | KMT2A 2426/4885LMNA 4192/4885SYK 723/4885 |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | HTR2C, HTR3B, TPH2 | KMT2A 1371/4885LMNA 749/4885SYK 2653/4885 |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | CASP3, BAX, CASP2 | KMT2A 4516/4885LMNA 117/4885SYK 4762/4885 |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | HTR2C, SYNCRIP, SFPQ | KMT2A 1172/4885LMNA 503/4885SYK 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.